Chunrong Tao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chunrong Tao has a total of 104 co-authors. Here are the top co-authors by number of shared publications:
- Rui Li
University of Science and Technology of China
10 shared publications - Wei Hu
University of Science and Technology of China
10 shared publications - Thanh N. Nguyen
Boston Medical Center
9 shared publications Tianlong Liu
Department of Neurology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China
9 shared publicationsChao Zhang
Department of Neurology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China
8 shared publications- Mohamad Abdalkader
Boston Medical Center
8 shared publications
Latest Publications
- Open Access
Endovascular thrombectomy alone versus intravenous thrombolysis plus endovascular thrombectomy on acute basilar artery occlusion (ATTENTION IV): study protocol for a multicentre randomised controlled trial
Introduction: The DEVT and DIRECT-MT trials showed that endovascular thrombectomy (EVT) alone is non-inferior to intravenous thrombolysis (IVT) followed by EVT in achieving 90-day functional independence for stroke patients with large-vessel occlusion (LVO). However, it is unclear whether EVT alone is non-inferior to IVT followed by EVT among patients with acute basilar artery occlusion (BAO). Therefore, additional studies are needed to explore the potential benefits of EVT alone in these patients. Methods and analysis: The ATTENTION IV trial is a prospective, multicentre, non-inferiority, blinded endpoint assessment, randomised controlled clinical trial to assess the effect of EVT alone compared with IVT plus EVT in acute BAO patients within 4.5 hours of symptom onset. Patients will be randomised in a 1:1 ratio to either the EVT-alone group or the IVT-plus-EVT group. A score of 0–2 on the 90-day modified Rankin Scale (mRS) was designated as the primary outcome for this study. Primary analysis will follow the intention-to-treat principle with a 15% non-inferiority margin. Secondary outcomes encompass functional status (mRS shift, excellent/good/fair outcomes), quality of life, early neurological recovery and radiological outcomes alongside safety endpoints of intracerebral haemorrhage and mortality. Ethics and dissemination: This study has been approved by the Ethics Committee of the First Affiliated Hospital of the University of Science and Technology of China (2023KY-055) and will be conducted following the Declaration of Helsinki. Study results will be published in peer-reviewed academic journals. Trial registration number: ClinicalTrials.gov ( NCT05827042 ).
Open AccessEndovascular thrombectomy alone versus intravenous thrombolysis plus endovascular thrombectomy on acute basilar artery occlusion (ATTENTION IV): study protocol for a multicentre randomised controlled trial
Introduction: The DEVT and DIRECT-MT trials showed that endovascular thrombectomy (EVT) alone is non-inferior to intravenous thrombolysis (IVT) followed by EVT in achieving 90-day functional independence for stroke patients with large-vessel occlusion (LVO). However, it is unclear whether EVT alone is non-inferior to IVT followed by EVT among patients with acute basilar artery occlusion (BAO). Therefore, additional studies are needed to explore the potential benefits of EVT alone in these patients. Methods and analysis: The ATTENTION IV trial is a prospective, multicentre, non-inferiority, blinded endpoint assessment, randomised controlled clinical trial to assess the effect of EVT alone compared with IVT plus EVT in acute BAO patients within 4.5 hours of symptom onset. Patients will be randomised in a 1:1 ratio to either the EVT-alone group or the IVT-plus-EVT group. A score of 0–2 on the 90-day modified Rankin Scale (mRS) was designated as the primary outcome for this study. Primary analysis will follow the intention-to-treat principle with a 15% non-inferiority margin. Secondary outcomes encompass functional status (mRS shift, excellent/good/fair outcomes), quality of life, early neurological recovery and radiological outcomes alongside safety endpoints of intracerebral haemorrhage and mortality. Ethics and dissemination: This study has been approved by the Ethics Committee of the First Affiliated Hospital of the University of Science and Technology of China (2023KY-055) and will be conducted following the Declaration of Helsinki. Study results will be published in peer-reviewed academic journals. Trial registration number: ClinicalTrials.gov ( NCT05827042 ).
- 11 August 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (3) , e218331
Exploring Between-Study Heterogeneity in Extended-Window IV Thrombolysis for Acute Ischemic Stroke
IV thrombolysis (IVT) is the standard-of-care evidence-based treatment of eligible patients with acute ischemic stroke (AIS) within 4.5 hours of symptom onset. Emerging evidence supports its use beyond this time window, leading to expanded recommendations for selected patients presenting between 4.5 and 24 hours. We performed a systematic review and meta-analysis to evaluate IVT in the 4.5- to 24-hour window and to explore sources of between-study heterogeneity. We searched MEDLINE, Cochrane Library, and ClinicalTrials.gov from inception through February 2026. Eligible studies were randomized controlled trials (RCTs) or individual patient-data meta-analyses of RCTs comparing IVT with control in patients with AIS presenting beyond 4.5 hours from last known well. The primary outcome was excellent functional recovery, defined as a modified Rankin Scale (mRS) of 0-1 at 90 days. Secondary outcomes included functional independence (mRS of 0-2 at 90 days); change in mRS disability, quantified as the common odds ratio (OR) for a 1-point improvement across the full ordinal mRS distribution (ordinal analysis); and safety measures such as 90-day mortality and symptomatic intracranial hemorrhage (sICH). Risk ratios (RRs) with 95% CIs were pooled. Multivariable meta-regression simultaneously modeled thrombolytic agent, endovascular thrombectomy context, and territory to disentangle confounded predictors. Fifteen studies representing 18 RCTs and encompassing 5,168 patients were included in the primary analysis. Of the 18 included RCTs, 11 required advanced perfusion imaging (CTP or MRP mismatch) or diffusion-weighted imaging/fluid-attenuated inversion recovery mismatch to confirm salvageable tissue; the remaining 7 permitted noncontrast CT/CT angiography-based selection. IVT significantly improved excellent functional outcome at 90 days (mRS 0-1; 40.3% vs 33.2%, RR 1.21; 95% CI 1.13-1.30; p < 0.001; number needed to treat [NNT] = 14) and good functional outcome (mRS 0-2; 54.5% vs 50.1%, RR 1.09; 95% CI 1.04-1.15; p < 0.001; NNT = 23). IVT was associated with significantly greater odds of reduced disability across the full mRS spectrum (common OR 1.18; 95% CI 1.07-1.32; p = 0.004). IVT increased the risk of sICH (3.2% vs 1.4%; RR 1.90; 95% CI 1.28-2.84; p = 0.002; number needed to harm = 57) but did not increase 90-day mortality (13.7% vs 13.0% RR 1.04; 95% CI 0.92-1.18; p = 0.53). Meta-regression showed that thrombectomy (β = -0.275, p = 0.012 for mRS shift; β = -0.186, p = 0.032 for mRS 0-2) is the primary driver of between-study heterogeneity, explaining 66%-100% of intertrial variance. Extended-window IVT improves functional outcomes across a wider spectrum of stroke subgroups than previously recognized. The benefit seems greatest for patients with more severe strokes in settings where thrombectomy is unavailable, providing the evidence base for offering a critical reperfusion strategy for the substantial proportion of patients worldwide who lack timely access to thrombectomy. This study provides American Academy of Neurology Class I evidence that IVT administered 4.5-24 hours after moderate-to-severe AIS onset in patients with salvageable tissue, where thrombectomy is not readily available, improves functional outcome at 90 days without increasing mortality.
- 11 August 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (3) , e218331
Exploring Between-Study Heterogeneity in Extended-Window IV Thrombolysis for Acute Ischemic Stroke
IV thrombolysis (IVT) is the standard-of-care evidence-based treatment of eligible patients with acute ischemic stroke (AIS) within 4.5 hours of symptom onset. Emerging evidence supports its use beyond this time window, leading to expanded recommendations for selected patients presenting between 4.5 and 24 hours. We performed a systematic review and meta-analysis to evaluate IVT in the 4.5- to 24-hour window and to explore sources of between-study heterogeneity. We searched MEDLINE, Cochrane Library, and ClinicalTrials.gov from inception through February 2026. Eligible studies were randomized controlled trials (RCTs) or individual patient-data meta-analyses of RCTs comparing IVT with control in patients with AIS presenting beyond 4.5 hours from last known well. The primary outcome was excellent functional recovery, defined as a modified Rankin Scale (mRS) of 0-1 at 90 days. Secondary outcomes included functional independence (mRS of 0-2 at 90 days); change in mRS disability, quantified as the common odds ratio (OR) for a 1-point improvement across the full ordinal mRS distribution (ordinal analysis); and safety measures such as 90-day mortality and symptomatic intracranial hemorrhage (sICH). Risk ratios (RRs) with 95% CIs were pooled. Multivariable meta-regression simultaneously modeled thrombolytic agent, endovascular thrombectomy context, and territory to disentangle confounded predictors. Fifteen studies representing 18 RCTs and encompassing 5,168 patients were included in the primary analysis. Of the 18 included RCTs, 11 required advanced perfusion imaging (CTP or MRP mismatch) or diffusion-weighted imaging/fluid-attenuated inversion recovery mismatch to confirm salvageable tissue; the remaining 7 permitted noncontrast CT/CT angiography-based selection. IVT significantly improved excellent functional outcome at 90 days (mRS 0-1; 40.3% vs 33.2%, RR 1.21; 95% CI 1.13-1.30; p < 0.001; number needed to treat [NNT] = 14) and good functional outcome (mRS 0-2; 54.5% vs 50.1%, RR 1.09; 95% CI 1.04-1.15; p < 0.001; NNT = 23). IVT was associated with significantly greater odds of reduced disability across the full mRS spectrum (common OR 1.18; 95% CI 1.07-1.32; p = 0.004). IVT increased the risk of sICH (3.2% vs 1.4%; RR 1.90; 95% CI 1.28-2.84; p = 0.002; number needed to harm = 57) but did not increase 90-day mortality (13.7% vs 13.0% RR 1.04; 95% CI 0.92-1.18; p = 0.53). Meta-regression showed that thrombectomy (β = -0.275, p = 0.012 for mRS shift; β = -0.186, p = 0.032 for mRS 0-2) is the primary driver of between-study heterogeneity, explaining 66%-100% of intertrial variance. Extended-window IVT improves functional outcomes across a wider spectrum of stroke subgroups than previously recognized. The benefit seems greatest for patients with more severe strokes in settings where thrombectomy is unavailable, providing the evidence base for offering a critical reperfusion strategy for the substantial proportion of patients worldwide who lack timely access to thrombectomy. This study provides American Academy of Neurology Class I evidence that IVT administered 4.5-24 hours after moderate-to-severe AIS onset in patients with salvageable tissue, where thrombectomy is not readily available, improves functional outcome at 90 days without increasing mortality.
- Open Access
- 2 June 2026
- Published by BMJ in Journal of NeuroInterventional Surgery
Association of tirofiban with outcomes in acute basilar artery occlusion: an etiology-stratified post hoc analysis of the ATTENTION trial
Background and purpose: Acute basilar artery occlusion (BAO) is a lethal neurovascular emergency where endovascular treatment (EVT) is limited by futile reperfusion. Tirofiban’s adjunctive use in BAO yields inconsistent findings, likely due to unaddressed etiological heterogeneity—relevant in Asian populations with high atherosclerotic (AS) prevalence but substantial non-AS subgroups. This pre-specified post hoc ATTENTION trial analysis explored potential etiology-specific associations between tirofiban and BAO-EVT outcomes. Methods: We included 221 patients with BAO who underwent EVT in the ATTENTION trial ( NCT04751708 ). Stroke etiology was categorized into AS and non-AS subgroups per the TOAST (Trial of ORG 10172 in Acute Stroke Treatment) criteria. Inverse probability of treatment weighting (IPTW) balanced baseline covariates (standardized mean difference <0.2), with doubly robust estimation to mitigate bias. Primary outcome was 90-day favorable function (modified Rankin Scale (mRS) 0–3). Safety outcomes included intracranial hemorrhage, symptomatic intracranial hemorrhage (sICH) at 24–72 hours, and 90-day mortality. Multivariate logistic regression analyzed outcomes, with pre-specified subgroup and likelihood ratio tests to explore tirofiban–etiology interactions. Results: Overall, tirofiban was not associated with favorable outcomes, mortality, or sICH. A potential interaction between tirofiban and etiology was observed for primary outcome (P=0.006). In non-AS BAO, tirofiban was associated with potentially improved reperfusion (97.1% vs 92.5%, P=0.016), higher favorable outcomes (adjusted OR (aOR) 2.06, 95% CI 1.21 to 3.54, P=0.009), and reduced mortality (P=0.036), with no increased bleeding risk. In AS BAO, no benefits were observed, and tirofiban was associated with increased futile reperfusion (P=0.043; P=0.012 for stroke etiology×tirofiban interaction). Conclusion: Tirofiban may be associated with favorable outcomes in non-AS BAO without increasing hemorrhagic risk, whereas it confers no clear benefit and may elevate futile reperfusion in AS BAO. These findings support the concept of etiology-specific adjunctive therapy in BAO and underscore the need for prospective investigations of tirofiban in non-AS BAO populations.
- 2 June 2026
- Published by BMJ in Journal of NeuroInterventional Surgery
Open AccessAssociation of tirofiban with outcomes in acute basilar artery occlusion: an etiology-stratified post hoc analysis of the ATTENTION trial
Background and purpose: Acute basilar artery occlusion (BAO) is a lethal neurovascular emergency where endovascular treatment (EVT) is limited by futile reperfusion. Tirofiban’s adjunctive use in BAO yields inconsistent findings, likely due to unaddressed etiological heterogeneity—relevant in Asian populations with high atherosclerotic (AS) prevalence but substantial non-AS subgroups. This pre-specified post hoc ATTENTION trial analysis explored potential etiology-specific associations between tirofiban and BAO-EVT outcomes. Methods: We included 221 patients with BAO who underwent EVT in the ATTENTION trial ( NCT04751708 ). Stroke etiology was categorized into AS and non-AS subgroups per the TOAST (Trial of ORG 10172 in Acute Stroke Treatment) criteria. Inverse probability of treatment weighting (IPTW) balanced baseline covariates (standardized mean difference <0.2), with doubly robust estimation to mitigate bias. Primary outcome was 90-day favorable function (modified Rankin Scale (mRS) 0–3). Safety outcomes included intracranial hemorrhage, symptomatic intracranial hemorrhage (sICH) at 24–72 hours, and 90-day mortality. Multivariate logistic regression analyzed outcomes, with pre-specified subgroup and likelihood ratio tests to explore tirofiban–etiology interactions. Results: Overall, tirofiban was not associated with favorable outcomes, mortality, or sICH. A potential interaction between tirofiban and etiology was observed for primary outcome (P=0.006). In non-AS BAO, tirofiban was associated with potentially improved reperfusion (97.1% vs 92.5%, P=0.016), higher favorable outcomes (adjusted OR (aOR) 2.06, 95% CI 1.21 to 3.54, P=0.009), and reduced mortality (P=0.036), with no increased bleeding risk. In AS BAO, no benefits were observed, and tirofiban was associated with increased futile reperfusion (P=0.043; P=0.012 for stroke etiology×tirofiban interaction). Conclusion: Tirofiban may be associated with favorable outcomes in non-AS BAO without increasing hemorrhagic risk, whereas it confers no clear benefit and may elevate futile reperfusion in AS BAO. These findings support the concept of etiology-specific adjunctive therapy in BAO and underscore the need for prospective investigations of tirofiban in non-AS BAO populations.
- Open Access
- 13 April 2026
- Published by BMJ in Stroke and Vascular Neurology
Extending the time window for intravenous tenecteplase in patients with distal medium vessel occlusions stroke: study protocol and rationale
Background: The TRACE III trial showed that for patients with large arterial occlusion presenting 4.5–24 hours of symptom occurrence and a salvageable penumbra on perfusion imaging, intravenous tenecteplase (TNK) thrombolysis is safe and can significantly improve patient outcomes in cases where endovascular thrombectomy is not feasible. However, it is currently unknown whether intravenous TNK thrombolysis beyond 4.5 hours can improve the outcomes of subjects with distal medium vessel occlusion (MeVO). Objective: To determine the safety and effectiveness of extended window TNK thrombolysis for MeVO stroke. Methods and design: Extending the Time Window for Intravenous TNK in Patients with Distal Medium Vessel Occlusions Stroke (TNK-MeVO) is a prospective, randomised, controlled, multicentre and open-label study with blinded outcome assessment. Up to 560 eligible subjects will be randomised 1:1 to receive TNK thrombolysis or standard medical management in over 40 comprehensive stroke centres across China. Outcomes: The primary endpoint is the rates of modified Rankin Scale score of 0–1 at 90 days. Safety endpoints include symptomatic intracerebral haemorrhage within 24 hours and mortality at 90 days. Conclusions: TNK-MeVO trial is designed to provide robust evidence on whether TNK thrombolysis is safe and effective for acute MeVO stroke presenting 4.5–24 hours of symptom onset. Trial registration number: NCT06559436 .
- 13 April 2026
- Published by BMJ in Stroke and Vascular Neurology
Open AccessExtending the time window for intravenous tenecteplase in patients with distal medium vessel occlusions stroke: study protocol and rationale
Background: The TRACE III trial showed that for patients with large arterial occlusion presenting 4.5–24 hours of symptom occurrence and a salvageable penumbra on perfusion imaging, intravenous tenecteplase (TNK) thrombolysis is safe and can significantly improve patient outcomes in cases where endovascular thrombectomy is not feasible. However, it is currently unknown whether intravenous TNK thrombolysis beyond 4.5 hours can improve the outcomes of subjects with distal medium vessel occlusion (MeVO). Objective: To determine the safety and effectiveness of extended window TNK thrombolysis for MeVO stroke. Methods and design: Extending the Time Window for Intravenous TNK in Patients with Distal Medium Vessel Occlusions Stroke (TNK-MeVO) is a prospective, randomised, controlled, multicentre and open-label study with blinded outcome assessment. Up to 560 eligible subjects will be randomised 1:1 to receive TNK thrombolysis or standard medical management in over 40 comprehensive stroke centres across China. Outcomes: The primary endpoint is the rates of modified Rankin Scale score of 0–1 at 90 days. Safety endpoints include symptomatic intracerebral haemorrhage within 24 hours and mortality at 90 days. Conclusions: TNK-MeVO trial is designed to provide robust evidence on whether TNK thrombolysis is safe and effective for acute MeVO stroke presenting 4.5–24 hours of symptom onset. Trial registration number: NCT06559436 .
- Open Access
- 7 April 2026
- Published by BMJ in Stroke and Vascular Neurology
Intravenous tenecteplase before endovascular thrombectomy in patients with acute basilar artery occlusion within 4.5–24 hours: study protocol and rationale
Background and purpose: One clinical trial demonstrated the beneficial effect of intravenous tenecteplase for large vessel occlusion patients not undergoing endovascular thrombectomy (EVT) within 4.5–24 hours. However, for those with acute basilar artery occlusion (BAO) presenting beyond the 4.5-hour therapeutic window, it remains unknown whether intravenous thrombolysis before EVT is beneficial. This study hypothesised that treatment of acute BAO patients with intravenous tenecteplase before EVT will result in better clinical outcomes vs EVT alone within 4.5–24 hours. Methods and design: ATTENTION LATE is a prospective, multicentre, randomised, controlled, open-label trial with blinded endpoint assessment. This study will enrol patients with acute BAO who present within 4.5–24 hours of symptom onset. These patients will be randomised 1:1 to either intravenous tenecteplase bridging to EVT or EVT alone. Study outcomes: A score of 0–2 on the modified Rankin Scale at 90 days will serve as the primary endpoint. Discussion: The ATTENTION LATE trial evaluates whether administering intravenous tenecteplase is safe and effective for acute BAO patients prior to EVT beyond the 4.5-hour time frame. This trial could establish the basis for expanding the eligible patient population to receive intravenous thrombolysis and extending the time window for acute BAO. Trial registration number: NCT05701956 .
- 7 April 2026
- Published by BMJ in Stroke and Vascular Neurology
Open AccessIntravenous tenecteplase before endovascular thrombectomy in patients with acute basilar artery occlusion within 4.5–24 hours: study protocol and rationale
Background and purpose: One clinical trial demonstrated the beneficial effect of intravenous tenecteplase for large vessel occlusion patients not undergoing endovascular thrombectomy (EVT) within 4.5–24 hours. However, for those with acute basilar artery occlusion (BAO) presenting beyond the 4.5-hour therapeutic window, it remains unknown whether intravenous thrombolysis before EVT is beneficial. This study hypothesised that treatment of acute BAO patients with intravenous tenecteplase before EVT will result in better clinical outcomes vs EVT alone within 4.5–24 hours. Methods and design: ATTENTION LATE is a prospective, multicentre, randomised, controlled, open-label trial with blinded endpoint assessment. This study will enrol patients with acute BAO who present within 4.5–24 hours of symptom onset. These patients will be randomised 1:1 to either intravenous tenecteplase bridging to EVT or EVT alone. Study outcomes: A score of 0–2 on the modified Rankin Scale at 90 days will serve as the primary endpoint. Discussion: The ATTENTION LATE trial evaluates whether administering intravenous tenecteplase is safe and effective for acute BAO patients prior to EVT beyond the 4.5-hour time frame. This trial could establish the basis for expanding the eligible patient population to receive intravenous thrombolysis and extending the time window for acute BAO. Trial registration number: NCT05701956 .
- 1 January 2026
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 318 (1) , e250734
Endovascular Therapy versus Medical Management for Basilar Artery Occlusion Presenting beyond 24 Hours
In patients with basilar artery occlusion treated beyond 24 hours from symptom onset, endovascular therapy was associated with higher odds of good functional status at 90 days compared with standard medical care.
- 1 January 2026
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 318 (1) , e250734
Endovascular Therapy versus Medical Management for Basilar Artery Occlusion Presenting beyond 24 Hours
In patients with basilar artery occlusion treated beyond 24 hours from symptom onset, endovascular therapy was associated with higher odds of good functional status at 90 days compared with standard medical care.
- Open Access
- 30 December 2025
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 18 (12) , 2277-2283
Remedial angioplasty or stenting in acute basilar artery occlusion: post hoc analysis of ATTENTION trial
Background and purpose: While endovascular therapy (EVT) is established for acute basilar artery occlusion (BAO), the clinical value of remedial angioplasty or stenting (RAS) is debated. This study investigated the efficacy and safety of RAS in patients with BAO undergoing EVT, the etiology dependent outcomes (atherosclerotic vs non-atherosclerotic outcomes), and the comparative effectiveness of balloon angioplasty versus stent based strategies. Methods: In this post hoc analysis of the prospective ATTENTION (Trial of Endovascular Treatment of Acute Basilar Artery Occlusion) multicenter trial, 221 patients with BAO receiving EVT were grouped into RAS (n=104) versus non-RAS groups (n=117). RAS included balloon angioplasty, stenting, or combined approaches. The primary outcome was 90 day favorable outcome (modified Rankin Scale score 0–3). Safety outcomes included any intracranial hemorrhage (ICH) and symptomatic ICH (sICH) at 24–72 hours, and 90 day mortality. Inverse probability of treatment weighting balanced baseline covariates, followed by multivariate logistic or ordinal regression for outcomes. Prespecified subgroup analyses by stroke etiology included interaction tests using stratified regression. Results: RAS showed no significant benefit for 90 day favorable outcomes (adjusted OR 0.81, 95% CI 0.55 to 1.19, P=0.282) despite lower ICH rates (OR 0.52, 0.28 to 0.92, P=0.027). RAS was associated with worse outcomes in non-atherosclerotic patients (P=0.003 for stroke etiology × RAS interaction), with no such effect in atherosclerotic cases. Balloon angioplasty alone showed comparable efficacy to stent based interventions (P=0.373). Conclusion: RAS did not improve functional outcomes in BAO overall and was associated with worse outcomes in non-atherosclerotic patients. Atherosclerotic subgroups may derive nuanced benefit, although further research is needed. Etiology tailored EVT strategies are warranted, with balloon angioplasty as a viable initial remedial option. Trial registration: ClinicalTrials.gov NCT04751708
- 30 December 2025
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 18 (12) , 2277-2283
Open AccessRemedial angioplasty or stenting in acute basilar artery occlusion: post hoc analysis of ATTENTION trial
Background and purpose: While endovascular therapy (EVT) is established for acute basilar artery occlusion (BAO), the clinical value of remedial angioplasty or stenting (RAS) is debated. This study investigated the efficacy and safety of RAS in patients with BAO undergoing EVT, the etiology dependent outcomes (atherosclerotic vs non-atherosclerotic outcomes), and the comparative effectiveness of balloon angioplasty versus stent based strategies. Methods: In this post hoc analysis of the prospective ATTENTION (Trial of Endovascular Treatment of Acute Basilar Artery Occlusion) multicenter trial, 221 patients with BAO receiving EVT were grouped into RAS (n=104) versus non-RAS groups (n=117). RAS included balloon angioplasty, stenting, or combined approaches. The primary outcome was 90 day favorable outcome (modified Rankin Scale score 0–3). Safety outcomes included any intracranial hemorrhage (ICH) and symptomatic ICH (sICH) at 24–72 hours, and 90 day mortality. Inverse probability of treatment weighting balanced baseline covariates, followed by multivariate logistic or ordinal regression for outcomes. Prespecified subgroup analyses by stroke etiology included interaction tests using stratified regression. Results: RAS showed no significant benefit for 90 day favorable outcomes (adjusted OR 0.81, 95% CI 0.55 to 1.19, P=0.282) despite lower ICH rates (OR 0.52, 0.28 to 0.92, P=0.027). RAS was associated with worse outcomes in non-atherosclerotic patients (P=0.003 for stroke etiology × RAS interaction), with no such effect in atherosclerotic cases. Balloon angioplasty alone showed comparable efficacy to stent based interventions (P=0.373). Conclusion: RAS did not improve functional outcomes in BAO overall and was associated with worse outcomes in non-atherosclerotic patients. Atherosclerotic subgroups may derive nuanced benefit, although further research is needed. Etiology tailored EVT strategies are warranted, with balloon angioplasty as a viable initial remedial option. Trial registration: ClinicalTrials.gov NCT04751708
- 1 November 2025
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 317 (2) , e251040
Endovascular Thrombectomy versus Standard Medical Management in Treatment of Acute Medium Vessel Occlusion Strokes: A Multicenter Registry
Compared with standard medical management, endovascular thrombectomy was associated with better outcomes in patients with acute medium vessel occlusion stroke, particularly those with more severe symptoms, without increasing symptomatic intracranial hemorrhage or 90-day mortality.
- 1 November 2025
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 317 (2) , e251040
Endovascular Thrombectomy versus Standard Medical Management in Treatment of Acute Medium Vessel Occlusion Strokes: A Multicenter Registry
Compared with standard medical management, endovascular thrombectomy was associated with better outcomes in patients with acute medium vessel occlusion stroke, particularly those with more severe symptoms, without increasing symptomatic intracranial hemorrhage or 90-day mortality.
- 12 August 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 105 (3) , e213911
Noncontrast CT vs CT Perfusion Imaging in Patients With Basilar Artery Occlusion
Acute CT perfusion (CTP) or MRI is not widely available or routinely performed across many stroke centers. We aimed to evaluate whether patients with acute basilar artery occlusion (BAO) who are selected by noncontrast CT (NCCT) for endovascular therapy (EVT) have similar outcomes compared with patients who are selected by CTP. This was a post hoc analysis of individual patient-level data from the ATTENTION and ATTENTION IA trials. Patients with BAO presenting within 24 hours of estimated onset and selected for EVT by NCCT were compared with those selected by CTP. The primary outcome was the 90-day modified Rankin Scale (mRS) score of 0-3. We used inverse probability of treatment weighting (IPTW) to account for confounders. Of 550 patients with BAO, 406 met eligibility criteria, of whom 274 (67.5%) were selected for EVT by NCCT and 132 (32.5%) were selected by CTP. The median (interquartile range, [IQR]) age was 67 (57-74) years, 70.7% were male, the median (IQR) baseline NIH Stroke Scale score was 23 (14-35), and the median (IQR) posterior circulation Acute Stroke Prognosis Early CT Score (pc-ASPECTS) was 9 (8-10). The primary outcome was similar in both NCCT and CTP groups (mRS scores 0-3: 48.5% vs 45.5%, p = 0.56, respectively). Functional independence at 90 days (mRS scores 0-2: 37.2% vs 33.3%, p = 0.44, respectively), symptomatic intracranial hemorrhage (4.5% vs 7.5%, p = 0.29), and 90-day mortality (32.1% vs 34.9%, p = 0.83) were similar in both groups, respectively. In IPTW analysis, there was no difference in mRS scores 0-3 at 90 days (odds ratio 0.88 [95% CI 0.58-1.32], p = 0.53). In patients with BAO treated with EVT up to the 24-hour time window, there was no difference in clinical or safety outcomes in patients selected by NCCT compared with CT perfusion. This study provides Class IV evidence that in patients with BAO, selection for EVT using NCCT yields similar clinical and safety outcomes compared with selection for EVT using CT perfusion. ATTENTION: ClinicalTrials.gov NCT04751708. ATTENTION IA: ClinicalTrials.gov NCT05684172.
- 12 August 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 105 (3) , e213911
Noncontrast CT vs CT Perfusion Imaging in Patients With Basilar Artery Occlusion
Acute CT perfusion (CTP) or MRI is not widely available or routinely performed across many stroke centers. We aimed to evaluate whether patients with acute basilar artery occlusion (BAO) who are selected by noncontrast CT (NCCT) for endovascular therapy (EVT) have similar outcomes compared with patients who are selected by CTP. This was a post hoc analysis of individual patient-level data from the ATTENTION and ATTENTION IA trials. Patients with BAO presenting within 24 hours of estimated onset and selected for EVT by NCCT were compared with those selected by CTP. The primary outcome was the 90-day modified Rankin Scale (mRS) score of 0-3. We used inverse probability of treatment weighting (IPTW) to account for confounders. Of 550 patients with BAO, 406 met eligibility criteria, of whom 274 (67.5%) were selected for EVT by NCCT and 132 (32.5%) were selected by CTP. The median (interquartile range, [IQR]) age was 67 (57-74) years, 70.7% were male, the median (IQR) baseline NIH Stroke Scale score was 23 (14-35), and the median (IQR) posterior circulation Acute Stroke Prognosis Early CT Score (pc-ASPECTS) was 9 (8-10). The primary outcome was similar in both NCCT and CTP groups (mRS scores 0-3: 48.5% vs 45.5%, p = 0.56, respectively). Functional independence at 90 days (mRS scores 0-2: 37.2% vs 33.3%, p = 0.44, respectively), symptomatic intracranial hemorrhage (4.5% vs 7.5%, p = 0.29), and 90-day mortality (32.1% vs 34.9%, p = 0.83) were similar in both groups, respectively. In IPTW analysis, there was no difference in mRS scores 0-3 at 90 days (odds ratio 0.88 [95% CI 0.58-1.32], p = 0.53). In patients with BAO treated with EVT up to the 24-hour time window, there was no difference in clinical or safety outcomes in patients selected by NCCT compared with CT perfusion. This study provides Class IV evidence that in patients with BAO, selection for EVT using NCCT yields similar clinical and safety outcomes compared with selection for EVT using CT perfusion. ATTENTION: ClinicalTrials.gov NCT04751708. ATTENTION IA: ClinicalTrials.gov NCT05684172.
- 24 April 2025
- Published by SAGE Publications in International Journal of Stroke
- Vol. 20 (6) , 763-768
Endovascular treatment in acute intracranial distal medium vessel occlusion stroke: Study protocol and rationale
Background: Distal medium vessel occlusions (MeVOs) account for an estimated 25% to 40% of all acute ischemic strokes. Emerging evidence from non-randomized trials suggest that endovascular thrombectomy (EVT) can achieve high rates of successful reperfusion in MeVO strokes, with a safety profile comparable to EVT for proximal arterial occlusions. These findings underscore the need for a prospective randomized clinical trial to evaluate the safety and efficacy of EVT for MeVO stroke. Objective: This trial aims to evaluate the safety and efficacy of EVT for MeVO stroke. Methods and design: Endovascular treatment in acute intracranial distal medium vessel occlusion stroke (ORIENTAL-MeVO) is an investigator-initiated, multicenter, prospective, randomized clinical trial with open-label treatment and blinded endpoint assessment (PROBE). Up to 564 eligible patients will be consecutively randomized in a 1:1 ratio to receive either EVT or standard of care over a period of 2 years in over 50 comprehensive stroke centers in China. Outcomes: The primary outcome is a shift in the distribution of the modified Rankin Scale (mRS) at day 90s with levels 5–6 combined (mRS = 0, 1, 2, 3, 4, 5–6). Primary safety endpoints include symptomatic intracerebral hemorrhage at 24 h and mortality at 90 days. Trial registration: ClinicalTrials.gov NCT06146790.
- 24 April 2025
- Published by SAGE Publications in International Journal of Stroke
- Vol. 20 (6) , 763-768
Endovascular treatment in acute intracranial distal medium vessel occlusion stroke: Study protocol and rationale
Background: Distal medium vessel occlusions (MeVOs) account for an estimated 25% to 40% of all acute ischemic strokes. Emerging evidence from non-randomized trials suggest that endovascular thrombectomy (EVT) can achieve high rates of successful reperfusion in MeVO strokes, with a safety profile comparable to EVT for proximal arterial occlusions. These findings underscore the need for a prospective randomized clinical trial to evaluate the safety and efficacy of EVT for MeVO stroke. Objective: This trial aims to evaluate the safety and efficacy of EVT for MeVO stroke. Methods and design: Endovascular treatment in acute intracranial distal medium vessel occlusion stroke (ORIENTAL-MeVO) is an investigator-initiated, multicenter, prospective, randomized clinical trial with open-label treatment and blinded endpoint assessment (PROBE). Up to 564 eligible patients will be consecutively randomized in a 1:1 ratio to receive either EVT or standard of care over a period of 2 years in over 50 comprehensive stroke centers in China. Outcomes: The primary outcome is a shift in the distribution of the modified Rankin Scale (mRS) at day 90s with levels 5–6 combined (mRS = 0, 1, 2, 3, 4, 5–6). Primary safety endpoints include symptomatic intracerebral hemorrhage at 24 h and mortality at 90 days. Trial registration: ClinicalTrials.gov NCT06146790.